Ceapro Announces Next Phase of Research Collaboration with the Angiogenesis Foundation
July 18 2023 - 8:05AM
Ceapro Inc. (TSX-V: CZO;
OTCQX: CRPOF) (“Ceapro” or the “Company”), a
growth-stage biotechnology company focused on the development and
commercialization of active ingredients for healthcare and cosmetic
industries, announced today the expansion of its collaboration with
the Angiogenesis Foundation to conduct research on characterizing
healing dynamics and molecular profiling of tissue regeneration
stimulated by oat-derived bioactives.
This next research phase is an extension of
previous studies demonstrating that Ceapro’s products have
biological activity. Work presented at the Annual Meeting of the
Wound Healing Society (WHS) in April 2023 showed that oat-based
beta glucan (BG) and avenanthramides (AV) reduce scar formation,
inhibit inflammation, recruit stem cells and stimulate angiogenesis
in vivo in a statistically significant manner compared to
control.
“A deeper understanding of how oat-derived
bioactives improve healing performance at the cellular and
molecular levels will allow for optimized product design and
improved patient outcomes,” commented Dr. Vincent W. Li, Chief
Scientific Officer of the Angiogenesis Foundation.
The goals of the new study will be to
investigate:
1) the impact of AV and
BG on the speed of wound healing at different time points;2) the
unique profile of AV and BG on skin healing dynamics;3) the
molecular profile of regenerative tissue repair by single cell RNA
analysis; and4) differential effects of AV and BG on gene
expression of the skin during tissue repair.
“While Ceapro has so far evolved in dermatology
by providing active ingredients serving the cosmetic sector,
additional expected evidence-based results from this study will not
only reinforce and/or add claims to existing cosmetics formulations
but should further position Ceapro in dermatology along with a
pharmaceutical and medical supplies partner who will benefit from
additional selling points arising from this unique research
program. This is in line with our vision to expand our business
model from an active ingredient provider to a life sciences
company,” commented Gilles R. Gagnon, M.Sc., MBA, President
and CEO of Ceapro.
About the Angiogenesis Foundation &
Disclosure
The Angiogenesis Foundation was founded in 1994
by a group of physicians, including Dr. William Li who is currently
the CEO of the Foundation and a board member of Ceapro Inc. The
Foundation is an independent 501(c)(3) scientific organization that
drives innovations in health promotion, disease prevention, and
disease treatment through research, education, and advocacy. The
Foundation has experience in developing rigorous, high-impact
scientific studies, including in the vascular and
immuno-inflammatory arenas that underlie chronic diseases in
oncology, cardiovascular diseases, and wound healing, and has
presented its results at national and international meetings, and
published in top tier scientific and clinical journals,
including Science, Nature, Lancet, and New
England Journal of Medicine. For more information or to support the
Foundation’s research and programs, visit angio.org.
About Ceapro Inc.
Ceapro Inc. is a Canadian biotechnology company
involved in the development of proprietary extraction technology
and the application of this technology to the production of
extracts and “active ingredients” from oats and other renewable
plant resources. Ceapro adds further value to its extracts by
supporting their use in cosmeceutical, nutraceutical, and
therapeutics products for humans and animals. The Company has a
broad range of expertise in natural product chemistry,
microbiology, biochemistry, immunology and process engineering.
These skills merge in the fields of active ingredients,
biopharmaceuticals and drug-delivery solutions. For more
information on Ceapro, please visit the Company’s website at
www.ceapro.com.
For more information
contact: Jenene Thomas JTC Team,
LLC Investor Relations and Corporate Communications
Advisor T (US): +1 (833) 475-8247 E:
czo@jtcir.com
Issuer:Gilles R. Gagnon, M.Sc., MBAPresident
& CEOT: 780-421-4555
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release
Ceapro (TSXV:CZO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ceapro (TSXV:CZO)
Historical Stock Chart
From Sep 2023 to Sep 2024